Cardiovascular disease is one of the leading causes of morbidity and mortality worldwide. Cardiometabolic diseases include obesity, diabetes and high blood pressure, all of which are becoming more common and are known to increase the risk of cardiovascular disease. Using validated and peer-reviewed approaches, we will define and assess subgroups based on the presence of cardiovascular and cardiometabolic disease. We will define groups of patients based on factors that have been shown to increase their risk and progression of cardiovascular disease, such as obesity, high lipoprotein(a) levels, metabolite levels (such as polyunsaturated fatty acids) and other novel factors. We will investigate the risk of the specifically defined populations in relation to cardiovascular events such as myocardial infarction, stroke, peripheral arterial disease, coronary artery bypass graft, percutaneous coronary intervention, cardiovascular death.
The specifically defined patient groups will allow assessment of treatment landscapes and the identification of the optimal target population for treatments and interventions. This will feed into the drug development process and thus subsequently may translate into better treatment options particularly where current treatment options are limited. In addition, specific patient population definition will allow assessment of safety and effectiveness of treatments.
This project aims to advance the knowledge of cardiovascular and cardiometabolic disease including the risk factors, characterise population subgroups with a cardiovascular unmet need and contribute to advancements to their treatment options. In addition, we will investigate long-term effectiveness of drugs for which there is limited evidence. Together, this project will help inform researchers, clinicians and patients to better understand and improve the cardiovascular and cardiometabolic health of the population.
